ArticleRand health quarterly2026
Advancing Development of LRRK2-Targeted Therapeutics for Parkinson's Disease: Conference Proceedings and Roadmap for Research.
Article in Rand health quarterly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Addressing the Challenges of Translating LRRK2 Biology into Disease-Modifying Therapies: The LRRK2 Investigative Therapeutics Exchange Initiative.Movement disorders : official journal of the Movement Disorder Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In June 2025, the Michael J. Fox Foundation for Parkinson's Research (MJFF) hosted an in-person workshop, LRRK2-Targeted Therapeutics Roundtable: Advancing Clinical Development for Parkinson's Disease, convening researchers, clinicians, industry representatives, and funders to discuss opportunities for communication, coordination, and collaboration to advance the development of therapeutics that target leucine-rich repeat kinase 2 (LRRK2). The purpose of this multistakeholder workshop was to create a collaborative platform for researchers, clinicians, industry representatives, and funders to discuss the trade-offs and opportunities in using various clinical trial strategies, including trade-offs and opportunities related to target populations, endpoints, treatment durations, and target labels. By fostering precompetitive dialogue on clinical development for LRRK2-targeted therapies, MJFF sought to ensure that sponsors design robust and informative clinical trials that can accelerate drug development and meaningfully advance efforts to deliver effective treatments to patients. In this study, the authors highlight the topics discussed in the workshop and outline the roundtable participants' immediate- and medium-term goals for advancing LRRK2-targeted research and therapeutic development. Key immediate actions mentioned during the roundtable include developing a comprehensive inventory of existing LRRK2 cohorts and their associated clinical and biologic data and biospecimens to find opportunities for data acquisition and harmonization. The authors also discuss what participants cited as the need to develop and validate LRRK2 pathway biomarkers to facilitate population identification and assessment of therapeutic efficacy, and to use these biomarkers to identify "LRRK2-like" individuals with idiopathic Parkinson's disease who exhibit LRRK2 pathway dysfunction.
Indexed as
Identifiers
41821671PMC12978670What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.